Yoram Padeh, MD
Allergy & Immunology · Aventura, FLNPI 1740266311
Payments from drug & device makers
Across 700 payments — averaging $73.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$34K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- AstraZeneca$4K
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$2K
- Sanofi$1K
- plus $5K from 27 others
What the payments were for
- Consulting fees$12,99525%
- Speaking & faculty fees$22,50044%
- Travel & lodging$1,6273%
- Food & beverage$14,24928%
- Education$1740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 60 | $33,754 |
| Takeda Pharmaceuticals U.S.A., Inc. | 148 | $4,076 |
| AstraZeneca | 43 | $3,722 |
| Regeneron Healthcare Solutions, Inc. | 88 | $1,871 |
| GSK | 102 | $1,850 |
| Sanofi | 48 | $1,483 |
| CSL Behring | 34 | $850 |
| Optinose US, Inc. | 23 | $612 |
| Galderma Laboratories, L.p. | 10 | $444 |
| Genentech USA, Inc. | 13 | $317 |
| Shire North American Group Inc | 22 | $283 |
| Biocryst US Sales Co., LLC | 14 | $218 |
| Pfizer | 13 | $213 |
| Kaleo, Inc. | 9 | $207 |
| Alk-abello, Inc | 7 | $188 |
| Novartis | 9 | $181 |
| Eyevance Pharmaceuticals LLC | 3 | $170 |
| AbbVie | 8 | $149 |
| Amgen | 7 | $141 |
| Aimmune Therapeutics, Inc. | 6 | $107 |
| Teva Pharmaceuticals USA, Inc. | 4 | $95 |
| Cycle Pharmaceuticals Inc | 3 | $91 |
| Octapharma USA, Inc. | 4 | $80 |
| Ionis Pharmaceuticals, Inc. | 4 | $79 |
| Verona Pharma, Inc. | 4 | $79 |
| Boehringer Ingelheim | 3 | $71 |
| Lilly USA, LLC | 2 | $44 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $33 |
| Grifols USA, LLC | 2 | $33 |
| Greer Laboratories, Inc. | 2 | $31 |
| Azurity Pharmaceuticals, Inc. | 1 | $30 |
| Blueprint Medicines Corporation | 1 | $23 |
| Organon | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,545 in reported general payments places this provider in the 80th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 21 | $1,090,691 |
| Dupixent PenDupilumab | 47 | $229,652 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $152,882 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $66,795 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $50,575 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $29,733 |
| XolairOmalizumab | 11 | $28,599 |
| DuleraMometasone/Formoterol | 19 | $9,037 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,479 |
| Epinephrine | 27 | $4,970 |
| Azelastine Hcl | 144 | $4,739 |
| Arnuity ElliptaFluticasone Furoate | 21 | $4,028 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,885 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 17 | $1,602 |
| Mometasone Furoate | 18 | $1,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Cuvitru | $4,076 | $1,243,57338 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,850 | $84,336151 claims |
| CSL BehringHizentra | $850 | $66,79524 claims |
| AstraZenecaSymbicort | $3,722 | $5,47916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Aventura
- Jaime LandmanAventura$3.9M
- Barry MarkAventura$15K
- Ileana RodicioMiami$3.8M
- Jose CarpioMiami$3.6M
- Michael KohenDaytona Beach$3.6M
- Thomas CasaleTampa$1.7M
- Dennis LedfordTampa$1.4M
- Ronald SaffTallahassee$1.2M
- Shahnaz FattehPlantation$1M
- Seong ChoTampa$969K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.